Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers

Background: The latest immunotherapy, used in the treatment of non-small cell lung cancer (NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) to inhibit its interaction with the PD-1 receptor. Elevated levels of PD-L1 expression were observed on NSCLC cells. The as...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Int J Mol Sci
Hauptverfasser: Pawelczyk, Konrad, Piotrowska, Aleksandra, Ciesielska, Urszula, Jablonska, Karolina, Glatzel-Plucinska, Natalia, Grzegrzolka, Jedrzej, Podhorska-Okolow, Marzenna, Dziegiel, Piotr, Nowinska, Katarzyna
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6413136/
https://ncbi.nlm.nih.gov/pubmed/30769852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20040824
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge